RWB
ORMP icon

RMR Wealth Builders’s Oramed Pharmaceuticals ORMP Stock Holding History

RMR Wealth Builders’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,300
Closed -$23K – 522
2021
Q1 		$23K Buy
2,300
+350
+18% +$2.87K 0.01% 489
2020
Q4 		$8K Buy
+1,950
New +$6.35K ﹤0.01% 427
2020
Q3 		– Sell
-450
Closed -$2K – 389
2020
Q2 		$2K Buy
+450
New +$1.51K ﹤0.01% 416
2019
Q4 		$2K Buy
+450
New +$1.69K ﹤0.01% 392

Other funds holding ORMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

RMR Wealth Builders's ORMP Position: Q2 2021 in Review

RMR Wealth Builders sold out of Oramed Pharmaceuticals (ORMP) in Q2 2021, closing a stake of 2,300 shares — an estimated $23K sold.

RMR Wealth Builders first reported a position in ORMP in Q4 2019 and held it in 4 quarters. The position peaked at $23K in Q1 2021. 75 funds tracked by Wall St. Rank hold ORMP as of Q2 2021.

  • RMR Wealth Builders reported no remaining Oramed Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • RMR Wealth Builders sold 2,300 Oramed Pharmaceuticals shares in Q2 2021, an estimated $23K.
  • RMR Wealth Builders first reported a position in Oramed Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • RMR Wealth Builders's Oramed Pharmaceuticals position peaked at $23K in Q1 2021.
  • 75 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2021.

Based on RMR Wealth Builders's 13F filing for Q2 2021, filed 16 Aug 2021.